Natural Remedies’ bacopa brain-health ingredients granted Natural Product Numbers from Health Canada

Article

The first NPN is for the company’s BacoMind Children ingredient, and the second NPN is for the company’s BacoMind Adult ingredient.

Photo © AdobeStock.com/Arundhati

Photo © AdobeStock.com/Arundhati

Natural Remedies (Bangalore, India) announced that its branded BacoMind Bacopa monnieri ingredients for brain health have been issued two Natural Product Numbers (NPN) from Health Canada.

The first NPN (#80111110) is for the company’s BacoMind Children ingredient. The NPN allows the health claims of “Helps to support cognitive function in children” and “Helps to support brain health in children.” It is recommended for use in children and teens aged 6-18 at a 225 mg daily dose.

The second NPN (#801111109) is for the company’s BacoMind Adult ingredient, which can be marketed with the claims “Supports brain health,” “Helps to support cognitive health and brain performance,” and “Helps to support memory.” The recommended dosage for adults is 300-450 mg daily.

Natural Remedies says BacoMind’s efficacy is substantiated by five human clinical studies in adults and children, including a human clinical safety study.1-4

References

  1. Morgan A et al. “Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial.Journal of Alternative and Complementary Medicine, vol. 16, no. 7 (July 2010): 753-759
  2. Harshad C et al. “Efficacy and tolerability of BacoMind®on memory improvement in elderly participants - A double blind placebo controlled study.” Journal of Pharmacology and Toxicology, vol. 3, no. 6 (2008): 425-434
  3. Usha PD et al. “BacoMind®: A cognitive enhancer in children requiring individual education programme.” Journal of Pharmacology and Toxicology, vol. 3, no. 4 (2008): 302-310
  4. Dave UP et al. “An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children.” Advances in Mind-Body Medicine, vol. 28, no. 2 (Spring 2014): 10-15
Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.